Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Blockade of IL-1b and PD-1 with combination chemotherapy reduces systemic myeloid suppression in metastatic pancreatic cancer with heterogeneous effects in the tumor

ABSTRACT: Blockade of IL-1b and PD-1 with combination chemotherapy reduces systemic myeloid suppression in metastatic pancreatic cancer with heterogeneous effects in the tumor

PROVIDER: PRJNA1113170 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Blockade of IL-1b and PD-1 with combination chemotherapy reduces systemic myeloid suppression in metastatic pancreatic cancer with heterogeneous effects in the tumor

Project description:Clinical and translational results from a phase Ib trial testing whether IL-1β blockade in human pancreatic cancer would alleviate myeloid immunosuppression and reveal anti-tumor T cell responses to PD-1 blockade.

2024-07-01 | GSE267814 | GEO

TGFβ blockade in pancreatic cancer enhances sensitivity to combination chemotherapy

Project description:We evaluated the TGFβ blocking antibody NIS793 in combination with either gemcitabine/n(ab)-paclitaxel or FOLFIRINOX chemotherapy in orthotopic pancreatic cancer. Blockade of TGFβ with chemotherapy reduced tumor burden in poorly immunogenic pancreatic cancer, without affecting the metastatic rate of cancer cells. TGFβ blockade decreased total aSMA+ fibroblasts but had minimal effect on fibroblast heterogeneity.

2023-04-23 | GSE224688 | GEO

Methionine Restriction Reduces Lung Cancer Progression and Increases Chemotherapy Response

Project description:Methionine Restriction Reduces Lung Cancer Progression and Increases Chemotherapy Response

| PRJNA1126222 | ENA

Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor.

Project description:Innate inflammation promotes tumor development, although the role of innate inflammatory cytokines in established human tumors is unclear. Herein, we report clinical and translational results from a phase Ib trial testing whether IL1β blockade in human pancreatic cancer would alleviate myeloid immunosuppression and reveal antitumor T-cell responses to PD1 blockade. Patients with treatment-naïve advanced pancreatic ductal adenocarcinoma (n = 10) were treated with canakinumab, a high-affinity monoclonal human antiinterleukin-1β (IL1β), the PD1 blocking antibody spartalizumab, and gemcitabine/n(ab)paclitaxel. Analysis of paired peripheral blood from patients in the trial versus patients receiving multiagent chemotherapy showed a modest increase in HLA-DR+CD38+ activated CD8+ T cells and a decrease in circulating monocytic myeloid-derived suppressor cells (MDSC) by flow cytometry for patients in the trial but not in controls. Similarly, we used patient serum to differentiate monocytic MDSCs in vitro and showed that functional inhibition of T-cell proliferation was reduced when using on-treatment serum samples from patients in the trial but not when using serum from patients treated with chemotherapy alone. Within the tumor, we observed few changes in suppressive myeloid-cell populations or activated T cells as assessed by single-cell transcriptional profiling or multiplex immunofluorescence, although increases in CD8+ T cells suggest that improvements in the tumor immune microenvironment might be revealed by a larger study. Overall, the data indicate that exposure to PD1 and IL1β blockade induced a modest reactivation of peripheral CD8+ T cells and decreased circulating monocytic MDSCs; however, these changes did not lead to similarly uniform alterations in the tumor microenvironment.

| S-EPMC11369625 | biostudies-literature

TGFβ blockade in pancreatic cancer enhances sensitivity to combination chemotherapy

Project description:TGFβ blockade in pancreatic cancer enhances sensitivity to combination chemotherapy

| PRJNA932122 | ENA

Tenacibaculum sp. 1B UA strain:1B UA

Project description:Tenacibaculum sp. 1B UA strain:1B UA Genome sequencing and assembly

| PRJNA810982 | ENA

Raoultella ornithinolytica strain:B1645-1B | isolate:B1645-1B

Project description:Raoultella ornithinolytica strain:B1645-1B | isolate:B1645-1B Genome sequencing

| PRJNA1000043 | ENA

Transcription profiling of human primary hematopoietic CD34+ cells to investigate Growth Factor Independence-1B (Gfi-1B) functions

Project description:Growth Factor Independence-1B (Gfi-1B) is a transcriptional repressor essential for erythropoiesis and megakaryopoiesis. Targeted gene disruption of Gfi-1B in mice leads to embryonic lethality due to failure to produce definitive erythrocytes, hindering the study of Gfi-1B function in adult hematopoiesis. We here show that, in humans, Gfi-1B controls the development of erythrocytes and megakaryocytes by regulating the proliferation and differentiation of bipotent erythro-megakaryocytic progenitors (MEP). We further identify in this cell population the type III transforming growth factor-? receptor gene, TGFBR3, as a direct target of Gfi-1B. Knock down of Gfi-1B results in altered TGF? signaling as shown by the increase in Smad2 phosphorylation and its inability to associate to the Transcription Intermediary Factor 1? (TIF1?). Because Smad2/TIF1? complex is known to specifically regulate erythroid differentiation, we propose that, by repressing the transforming growth factor-? receptor III (T?R?II) expression, Gfi-1B favors the Smad2/TIF1? interaction downstream of TGF? signaling, allowing immature progenitors to differentiate toward the erythroid lineage.

2010-04-19 | E-MEXP-2560 | biostudies-arrayexpress

Methionine Restriction Reduces Lung Cancer Progression and Increases Chemotherapy Response

Project description:Methionine restriction sensitizes A549 cells with and without LKB1 to chemotherapy

2024-07-19 | GSE270333 | GEO

Lysobacter sp. FW306-1B-D06B isolate:FW306-1B-D06B

Project description:Lysobacter sp. FW306-1B-D06B isolate:FW306-1B-D06B Genome sequencing

| PRJNA1101089 | ENA